VistaGen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Three months ended June 30, 2015, the first quarter of fiscal 2016. The filing is unaudited. VistaGen is a clinical-stage biopharmaceutical company with no current product revenue; its lead candidate, AV-101, is being developed for major depressive disorder (MDD), alongside stem-cell-based drug-rescue and regenerative-medicine programs.
Key financial metrics
| Metric | Quarter ended June 30, 2015 | Comparable 2014 period / balance-sheet comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $372,600 | $473,600; down 21% |
| General and administrative expense | $1,448,500 | $797,200; up 82% |
| Operating loss | $1,821,100 | $1,270,800 |
| Net loss | $29,524,100 | $4,553,300 |
| Net loss attributable to common stockholders; loss per share | $29,993,600; $19.23 basic and diluted | $4,553,300; $3.70 basic and diluted |
| Cash used in operating activities | $823,300 | $1,011,800 |
| Cash and cash equivalents | $121,000 | $70,000 at March 31, 2015 |
| Total assets / total liabilities | $1,743,800 / $4,609,700 | $269,700 / $20,812,500 at March 31, 2015 |
| Current assets / current liabilities | $1,594,300 / $3,278,700 | $105,700 / $17,388,100 at March 31, 2015 |
Margins are not meaningful because the company reported no revenue. At June 30, 2015, the working-capital deficit was approximately $1.68 million and stockholders’ deficit was $2.87 million. Notes payable were approximately $1.38 million in total, excluding capital leases; the balance sheet reported no remaining convertible-note balance.
Material changes and unusual items
- The quarterly net loss included a $25.05 million loss on extinguishment of debt, principally a non-cash accounting charge. VistaGen converted approximately $15.4 million of debt and related obligations into Series B preferred stock and, for some conversions, warrants. The charge materially increased reported net loss; operating cash used was $823,300.
- In May 2015, VistaGen created Series B 10% convertible preferred stock. Shares generally convert into common stock at $7 per share, accrue dividends payable in common shares, and may convert automatically upon specified financing, strategic-transaction, or share-price conditions.
- The company’s debt restructuring also released Platinum’s security interests in company assets. The warrant liability was eliminated after amendments fixed warrant exercise prices and removed reset provisions.
- G&A expense rose 82%, mainly reflecting professional fees and $500,000 of common stock issued for corporate-development services, $250,000 of preferred stock issued for legal services, and warrant-modification expense. R&D expense declined 21%.
- Cash from financing activities was $874,300, including $607,500 of Series B unit proceeds and $280,000 from common-stock, warrant, and unit issuances. Financing proceeds exceeded operating cash use, increasing cash by $51,000.
Outlook, liquidity, and risks
- Management stated that June 30 cash was insufficient to fund planned operations for the next 12 months, with expected cash expenditures of approximately $6 million. The filing describes recurring losses and negative operating cash flows and warns that unavailable or delayed financing could force reductions, deferrals, or discontinuation of development activities and could threaten the company’s ability to continue as a going concern.
- VistaGen expected to pursue additional financing, collaborations, licensing arrangements, and grants, while controlling costs. It gave no specific financial guidance.
- Under a February 2015 agreement, the NIH/NIMH was to conduct and fully fund the initial Phase 2 AV-101 study in treatment-resistant MDD; the company expected the study to begin in the second half of 2015. Timing and results were uncertain.
- After quarter-end through August 11, VistaGen reported $2.05 million of cash proceeds from Series B unit sales, including $1.0 million from an affiliate of Platinum; Platinum separately agreed to purchase an additional $3.0 million of units between August 15 and October 15, 2015. The commitment was not cash received at June 30. The company also reported post-quarter debt and payables conversions, including $1.68 million described in the financial-statement notes.
- Principal risks include the need for substantial additional capital; AV-101’s clinical, regulatory, and commercialization uncertainty; dependence on third parties for clinical trials and manufacturing; and potential dilution from preferred stock, warrants, and future financing. The filing also notes that AV-101 had no issued patents at the time.
Important facts for investors to verify
- Whether post-quarter financing was completed, including Platinum’s additional $3.0 million commitment, and how much usable cash remained.
- The timing, enrollment, funding scope, and subsequent results of the NIH/NIMH-sponsored AV-101 Phase 2 study.
- The terms and accounting effects of the Series B conversions, accrued dividends, conversion features, and outstanding warrants, including potential dilution.
- The company’s cash runway and ability to meet obligations, given $121,000 of quarter-end cash and management’s stated 12-month funding shortfall.
- The reconciliation of post-quarter debt-conversion amounts: the notes describe $1.678 million in one disclosure and approximately $1.561 million in another; the filing text does not provide a clear reconciliation.
Management concluded that disclosure controls and procedures were effective at quarter-end. The company reported no legal proceedings, defaults upon senior securities, or off-balance-sheet arrangements.